Abstract: Anemia is common observed in lung cancer patients, and it is mainly caused by chemotherapy. Anemia can cause several debilitating symptoms such as fatigue and tachycardia which will not only influence the patients’ quality of life and therapy effect, but also short the survival time. So anemia has been regarded as a poor independent prognostic indicator of the disease. Transfusion the erythrocyte and using the erythropoiesis stimulating agents is the main treatments of the disease. Using the erythropoiesis stimulating agents is the main treatment before the hemoglobin decreasing significantly in order to reduce the times of transfusion. Keeping the hemoglobin between 10.0-12.0 g/dl can improve the patients’ quality of life and avoid the adverse events such as thrombus formation at the same time.

Key words: Anemia, Lung neoplasms, Therapeutics